[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The First Affiliated Hospital of Xiamen University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":594},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,60,0,25,[9,49,72,93,114,138,171,195,217,242,266,285,308,330,350,376,400,423,449,472,492,512,532,555,575],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100645163","dll3-targeted-petct-in-small-cell-lung-cancer-100645163",false,"NCT07677787","DLL3-Targeted PET\u002FCT in Small Cell Lung Cancer","Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Small Cell Lung Cancer","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with suspected, newly diagnosed, and previously treated small cell lung cancer(supporting evidence may include imaging findings and pathology report);\n* Serum ProGRP or NSE level ≥ 3 times the upper limit of normal;\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n* Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.\n* Inability to complete PET\u002FCT imaging.","ALL","18 Years","80 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET\u002FCT in patients with suspected or histologically confirmed small cell lung cancer, and to compare with conventional imaging modalities.",[28,29,30,31],"PET\u002FCT","Small Cell Lung Cancer ( SCLC )","DLL3-targeted PET\u002FCT","Delta-like Protein 3",[30,28,33,34,35],"Small Cell Lung Cancer","SCLC","Delta-like protein 3","RECRUITING","2026-06-25",{"date":39,"type":40},"2026-07-01","ACTUAL",{"date":42,"type":40},"2026-05-09",{"date":44,"type":22},"2028-05-31",{"name":46,"class":47},"The First Affiliated Hospital of Xiamen University","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":71,"locationsCount":48},"100645208","gpc3-targeted-petct-in-hepatocellular-carcinoma-100645208","NCT07677774","GPC3-Targeted PET\u002FCT in Hepatocellular Carcinoma","Glypian-3 (GPC3)- Targeted PET Imaging in Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with suspected, newly diagnosed, or previously treated hepatocellular carcinoma(supporting evidence may include imaging findings and pathology report);\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n* Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.\n* Inability to complete PET\u002FCT imaging.",{"count":57,"type":22},40,[25],"The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET\u002FCT in patients with suspected or histologically\u002Fclinically confirmed hepatocellular carcinoma, and to compare with 18F-FDG PET\u002FCT.",[61,62,63],"Hepatocellular Carcinoma (HCC)","Glypican-3","GPC3-targeted PET\u002FCT",[65,62,63,66,28],"Hepatocellular Carcinoma","HCC",{"date":39,"type":40},{"date":69,"type":40},"2026-05-01",{"date":44,"type":22},{"name":46,"class":47},{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":48},"100603215","the-effect-of-transcutaneous-electrical-acupoint-stimulation-on-postoperative-gastrointestinal-dysfunction-after-urological-laparoscopic-surgery-100603215","NCT07133620","the Effect of Transcutaneous Electrical Acupoint Stimulation on Postoperative Gastrointestinal Dysfunction After Urological Laparoscopic Surgery","The Effect of Transcutaneous Electrical Acupoint Stimulation on Postoperative Gastrointestinal Dysfunction After Urological Laparoscopic Surgery","Inclusion Criteria:\n\n* Age \\> 18 years\n* BMI \\\u003C 28 kg\u002Fm2\n* ASA classification is I-III grade\n* Laparoscopic urological procedures under general anesthesia, including but not limited to laparoscopic nephrectomy and laparoscopic radical prostatectomy for prostate cancer\n* Normal comprehension ability, and the patient or his\u002Fher family members can cooperate in filling out the questionnaire\n* Voluntary to sign the informed consent form\n\nExclusion Criteria:\n\n* Comprehensive assessment of severe cardiovascular, pulmonary and cerebrovascular diseases (such as severe coronary heart disease, valve diseases, respiratory failure, cerebral hemorrhage, cerebral infarction, etc.)\n* Preoperative use of analgesic and gastrointestinal motility drugs\n* TEAS contraindications (having electronic devices in the body, skin damage or infection at the stimulation site)\n* Previous history of TEAS or electro-acupuncture treatment\n* Previous history of gastrointestinal surgery, long-term gastrointestinal motility disorders and severe intestinal diseases\n* Pregnancy",{"count":80,"type":22},112,[25],"The purpose of this clinical trial is to understand the effect of percutaneous acupoint electrical stimulation on postoperative gastrointestinal dysfunction. It will also investigate the safety of percutaneous acupoint electrical stimulation. The main questions that this trial aims to answer are:\n\nCan percutaneous acupoint electrical stimulation alleviate postoperative gastrointestinal dysfunction? Through which mechanisms do they function?\n\nParticipants will:\n\nPreoperatively, patients were either given or not given percutaneous acupoint electrical stimulation.\n\nRecord their symptoms and biological indicators within 5 days after the operation.",[84],"Postoperative Gastrointestinal Dysfunction (POGD)","2026-06-22",{"date":87,"type":40},"2026-06-24",{"date":89,"type":40},"2025-11-01",{"date":91,"type":22},"2026-11-30",{"name":46,"class":47},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":113,"locationsCount":48},"100640271","early-phase-1-human-umbilical-cord-mesenchymal-stem-cell-derived-small-extracellular-vesicles-for-the-treatment-of-dry-eye-disease-100640271","NCT07623382","Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease","Clinical Study on the Treatment of Dry Eye With Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles Eye Drops","Inclusion Criteria:\n\n* Subjects who voluntarily participate and sign the informed consent form, are willing to comply with the treatment schedule specified in the study protocol, and attend follow-up visits on time.\n* Aged ≥ 18 years, with no gender restriction.\n* Best-corrected visual acuity (BCVA) of both eyes (OU) ≥ 0.1 at the Screening Visit (Visit 1, V1).\n* History of dry eye disease in both eyes prior to the Screening Visit (Visit 1, V1), with at least one of the following subjective symptoms: ocular dryness, foreign body sensation, burning sensation, eye fatigue, discomfort, redness, or fluctuating visual acuity.\n* Meeting one of the following criteria at the Screening Visit (Visit 1, V1):\n\n  i. Positive corneal fluorescein staining, TBUT \\\u003C 10 s, and OSDI score ≥ 13; ii. Negative corneal fluorescein staining, TBUT \\\u003C 5 s, and OSDI score ≥ 13\n\nExclusion Criteria:\n\n* Subjects with current ocular herpes or any other ocular infection or inflammation, or a history of ocular herpes or any other ocular infection within 30 days prior to screening.\n* Subjects with ocular diseases including structural abnormalities of the eyelid margin (ectropion, entropion, eyelid laxity, etc.), severe conjunctivochalasis, Salzmann nodular corneal degeneration, damaged conjunctival goblet cells (e.g., vitamin A deficiency), progressive pterygium, wet age-related macular degeneration (wAMD), glaucoma, diabetic retinopathy, retinal vein occlusion, etc., which, in the investigator's opinion, may increase subject risk or interfere with study outcomes.\n* Subjects with secondary ocular scarring that, in the investigator's assessment, may affect subject compliance or outcome evaluation (e.g., radiation scars, chemical burns, Stevens-Johnson syndrome, cicatricial pemphigoid, etc.).\n* Subjects with secondary Sjögren's syndrome or other autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.), unless the subject meets all of the following conditions:\n\n  1. Not receiving steroids, immunomodulatory, or immunosuppressive agents for the disease;\n  2. The investigator determines that the medical condition will not impact study results.\n* Subjects with a history of organ or bone marrow transplantation.\n* Subjects who wore contact lenses within 30 days prior to screening.\n* Subjects who received physical therapy for dry eye within 30 days prior to screening, including eyelid scrubbing, meibomian gland expression, warm compresses, fuming, or IPL laser therapy for bilateral dry eye.\n* Subjects who received oral aspirin or aspirin-containing medications, or used NSAIDs (topical ocular or systemic), or drugs known to induce ocular dryness (e.g., anticholinergics, SSRIs, etc.) within 30 days before dosing, unless the subject has been on a stable dose of such medication for at least 30 days before the baseline visit, with no expected changes during the study.\n* Subjects who used the following medications within the specified periods before dosing:\n\n  1. Antihistamines (ocular or systemic) or any topical ophthalmic medications within 14 days before dosing;\n  2. Artificial tears within 14 days before dosing;\n  3. Steroids or mast cell stabilizers (ocular or systemic) within 30 days before dosing;\n  4. Varenicline or diquafosol within 30 days before dosing;\n  5. Topical ocular cyclosporine or tacrolimus within 6 weeks before dosing.\n* Subjects with punctal plugs implantation or a history of punctal cautery within 12 weeks prior to screening.\n* Subjects who used antiglaucoma medications within 3 months prior to screening, had non-laser glaucoma surgery, or underwent glaucoma laser surgery within 6 months prior to the screening visit.\n* Subjects who underwent Nd:YAG laser capsulotomy within 6 months prior to screening, or corneal refractive surgery (e.g., LASIK) within 12 months prior to screening.\n* Subjects with known allergy to fluorescein, multiple drug allergies, or severe allergic diseases.\n* Subjects with other poorly controlled clinical conditions, such as severe chronic infection, severe cardiopulmonary disease, uncontrolled hypertension (defined as systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg despite antihypertensive treatment), uncontrolled diabetes mellitus, malignant tumors, etc.\n* Female subjects with a positive pregnancy test or lactating subjects; female subjects of childbearing potential or male subjects whose partners are of childbearing potential who are unwilling to use contraception during the study and for 1 month after the last dose of study medication.\n* Subjects who participated in any other clinical trial of investigational drugs or devices within 30 days prior to screening.\n* Any other conditions deemed by the investigator to make the subject ineligible for enrollment (e.g., depression, etc.).",{"count":21,"type":22},[102],"EARLY_PHASE1","This clinical trial aims to preliminarily evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell small extracellular vesicle eye drops in patients with dry eye disease.\n\n1. Human mesenchymal stem cell small extracellular vesicle eye drops:\n\n   Administer one drop each time, 4 times daily, for a treatment duration of 4 weeks.\n2. During treatment, subjects will be followed up and undergo examinations and related tests weekly.\n3. After completion of treatment, follow-up visits will be conducted every 2 weeks for a total of 2 visits.\n4. Subsequently, subjects will enter a long-term follow-up period, with follow-up assessments at 3 months and 6 months to observe longer-term safety and efficacy.\n5. Subjects shall record medication usage and any possible adverse reactions.",[105,106],"Dry Eye Disease","Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles","2026-05-28",{"date":109,"type":40},"2026-06-03",{"date":111,"type":40},"2026-03-31",{"date":91,"type":22},{"name":46,"class":47},{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":17,"minAge":18,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":137,"locationsCount":48},"100574058","68ga-nk224-pet-imaging-of-pd-l1-expression-in-cancers-100574058","NCT06754345","68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order);\n* (ii) patients with newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report);\n* (iii) patients who had scheduled 68Ga-NK224 PET\u002FCT scans;\n* (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions;\n* (ii) patients with pregnancy;\n* (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"90 Years",{"count":123,"type":22},100,"OBSERVATIONAL","To evaluate the potential usefulness of 68Ga-NK224 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the evaluation of PD-L1 expression in primary and\u002For metastatic tumors, compared with histopathological results.",[127,128],"Tumor","PD-L1",[127,128,28,130],"diagnosis","2026-05-13",{"date":133,"type":40},"2026-05-15",{"date":135,"type":40},"2023-05-30",{"date":91,"type":22},{"name":46,"class":47},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":151,"conditions":152,"keywords":156,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":48},"100635072","phase-2-tofacitinib-for-glucocorticoid-resistant-moderate-to-severe-thyroid-eye-disease-100635072","NCT07547930","Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease","A Single-Arm, Open-Label, Exploratory Study of Tofacitinib in Patients With Glucocorticoid-Resistant or Intolerant Moderate-to-Severe Active Thyroid Eye Disease","TOFA-GO","Inclusion Criteria:\n\n1. Age and Gender: Male or female participants aged 18 to 75 years (inclusive).\n2. Diagnosis: Clinical diagnosis of Graves' orbitopathy (GO) consistent with EUGOGO criteria.\n3. Severity: Moderate-to-severe GO as defined by EUGOGO guidelines (impact on daily life, but not sight-threatening).\n4. Activity: Active disease, defined as a Clinical Activity Score (CAS) \\>=3 points (on the 7-point scale).\n5. Refractory Status (Must meet ONE of the following):Glucocorticoid-Resistant: Failure to respond (no significant improvement in proptosis or CAS) after receiving a cumulative dose of at least 3g of intravenous methylprednisolone (or equivalent).Glucocorticoid-Intolerant: Documented contraindications to high-dose systemic glucocorticoids (e.g., uncontrolled diabetes mellitus, severe osteoporosis, glaucoma, severe psychiatric disorders) or history of severe adverse events leading to discontinuation.\n6. Thyroid Function: Euthyroid or mild hypothyroidism\u002Fhyperthyroidism maintained on stable antithyroid drugs or thyroxine replacement therapy for at least 4 weeks prior to baseline.\n7. Contraception: Women of childbearing potential must agree to use effective contraception during the study period and for at least 4 weeks after the last dose of the study drug.\n8. Consent: Willing and able to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* 1.Sight-Threatening Disease: Presence of Dysthyroid Optic Neuropathy (DON) or severe corneal breakdown requiring immediate surgical intervention.\n\n  2.Chronic\u002FInactive Disease: Fibrotic or burnout stage of GO with a Clinical Activity Score (CAS) \\\u003C 3.\n\n  3.Prior Orbital Treatment:Orbital radiotherapy at any time.Orbital surgical decompression at any time.Strabismus surgery or eyelid surgery within 3 months prior to baseline.\n\n  4.Concomitant Immunomodulation: Use of other biologic agents (e.g., Teprotumumab, Rituximab, Tocilizumab) within 3 months prior to baseline.\n\n  5.Active Infection Risk (Critical for JAK Inhibitors):Active tuberculosis (TB) or untreated latent TB.Active or chronic Hepatitis B or Hepatitis C infection.Human Immunodeficiency Virus (HIV) infection.History of disseminated herpes zoster or herpes simplex.Any severe active infection requiring hospitalization or IV antibiotics within 4 weeks of baseline.\n\n  6.Thrombosis Risk: History of venous thromboembolism (VTE), including deep vein thrombosis (DVT) or pulmonary embolism (PE), or known coagulation disorders.\n\n  8.Malignancy: History of any malignancy within the past 5 years (except adequately treated basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix).\n\n  9.Laboratory Abnormalities:Absolute Neutrophil Count (ANC) \\\u003C 1.0 \\*10\\^9\u002FL and\u002For Absolute Lymphocyte Count (ALC) \\\u003C 0.5 \\*10\\^9\u002FL and \u002For Hemoglobin \\\u003C 90 g\u002FL and\u002For AST or ALT \\> 2\\* Upper Limit of Normal (ULN) and\u002For Estimated Glomerular Filtration Rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m²","75 Years",{"count":148,"type":22},8,[150],"PHASE2","Thyroid Eye Disease (TED), also known as Graves' orbitopathy, is an autoimmune condition that causes inflammation and tissue expansion behind the eyes, leading to bulging eyes (proptosis), double vision, and pain. Currently, intravenous glucocorticoids (steroids) are the standard first-line treatment. However, approximately 20-30% of patients do not respond to steroids, or cannot tolerate their side effects.\n\nThis study aims to evaluate the safety and efficacy of Tofacitinib, an oral medication known as a Janus kinase (JAK) inhibitor, as a rescue therapy for these difficult-to-treat cases. Tofacitinib works by blocking specific signaling pathways (JAK-STAT) that drive inflammation and fibrosis in the eye socket. In this study, patients with moderate-to-severe active TED who are resistant to or intolerant of steroids will receive Tofacitinib tablets (5 mg twice daily) for 24 weeks. The researchers will assess whether the treatment can effectively reduce eye bulging and improve clinical activity scores.",[153,154,155],"Thyroid Eye Disease, TED","Graves Ophthalmopathy","Graves Orbitopathy",[157,158,159,160,161,162],"Tofacitinib","Refractory Thyroid Eye Disease","Graves' Orbitopathy","JAK Inhibitor","Steroid-resistant","Glucocorticoid-resistant","2026-04-28",{"date":165,"type":40},"2026-04-29",{"date":167,"type":40},"2026-04-24",{"date":169,"type":22},"2027-12-30",{"name":46,"class":47},{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":146,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":48},"100592385","phase-2-trilaciclib-in-patients-receiving-sacituzumab-tirumotecan-for-egfr-mutated-advanced-non-small-cell-lung-cancer-nsclc-100592385","NCT06992739","Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)","A Prospective, Single-arm Phase II Trial of Trilaciclib Administered Prior to Sacituzumab Tirumotecan in Patients With EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors（PROTECT-2）","PROTECT-2","Inclusion Criteria:\n\n1. Age range: 18-75 years old; No gender restrictions;\n2. ECOG PS score 0-1;\n3. Expected survival time ≥ 3 months;\n4. Patients with locally advanced or metastatic EGFR mutant non-small cell lung cancer diagnosed by histological or cytological examination, who have failed third-generation EGFR-TKI treatment and have experienced up to second-line EGFR-TKI treatment failure;\n\n   1. Patients who have only progressed with 1-2 generations of EGFR-TKI treatment need to undergo third-generation EGFR-TKI treatment;\n   2. If patients receive third-generation EGFR-TKI during neoadjuvant and\u002For postoperative adjuvant therapy and progress to metastatic or locally advanced disease more than 6 months after the last dose, they need to receive third-generation EGFR-TKI treatment again before they can participate in this study;\n   3. If patients receive third-generation EGFR-TKI during neoadjuvant and\u002For postoperative adjuvant therapy and progress to metastatic or locally advanced disease within 6 months after the last dose, they can directly participate in this study;\n   4. Imaging disease progression was recorded during or after the recent first-line treatment process.\n5. There must be at least one measurable lesion that meets the RECIST 1.1 criteria;\n6. The main organ functions well and meets the following standards:\n\n   Blood routine examination (without blood transfusion or correction with hematopoietic stimulating factor drugs within 14 days): hemoglobin (Hb) ≥ 90g\u002FL; Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL; Platelet count (PLT) ≥ 80 × 109\u002FL; Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver metastasis); Serum total bilirubin (TBIL) ≤ 1.5 × ULN (Gilbert syndrome subjects, ≤ 3×ULN）； Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance rate ≥ 60mL\u002Fmin; Coagulation function: activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) ≤ 1.5 × ULN;\n7. The subject must recover from all toxic reactions (except hair loss) of previous treatment to ≤ level 1 (evaluated based on CTCAE 5.0 criteria);\n8. Women: All women with potential fertility must have a negative serum pregnancy test result during the screening period, and must take reliable contraceptive measures from signing the informed consent form until 3 months after the last dose;\n9. Participants voluntarily participate in this study, understand and sign the informed consent form.\n\nExclusion Criteria:\n\n1. History of myeloid leukemia, myelodysplastic syndrome, or accompanying sickle cell disease;\n2. Symptomatic CNS metastases and\u002For leptomeningeal diseases that require immediate radiotherapy or steroid treatment;\n3. Have undergone surgery or radiation therapy within 4 weeks prior to the administration of the first dose of the study drug;\n4. Clinical symptoms or diseases of the heart that have not been well controlled, such as: (1) NYHA grade 2 or above heart failure; (2) Unstable angina pectoris; (3) Have experienced myocardial infarction within 6 months; (4) Patients with clinically significant supraventricular or ventricular arrhythmias that require treatment or intervention;\n5. History of interstitial lung disease, slow progressive dyspnea and dry cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary allergic pneumonia, or multiple allergic or peripheral arterial diseases (such as claudication, Leo Buerger's disease).\n6. Patients who have received hematopoietic stem cell or bone marrow transplantation in the past;\n7. Patients who need to receive radiation therapy at the same time;\n8. Those who are known to have a history of allergies to the components of this drug regimen;\n9. Pregnant or lactating women;\n10. The researcher believes that the patient is not suitable to participate in any other circumstances of this study.",{"count":180,"type":22},49,[150],"This study is a prospective, single arm phase II clinical trial aimed at patients with advanced non-small cell lung cancer resistant to EGFR-TKI. The aim is to evaluate the efficacy and safety of trilaciclib in bone marrow protection before monotherapy with sacituzumab tirumotecan.\n\nPatients with advanced non-small cell lung cancer resistant to EGFR-TKI, after signing informed consent, will be screened for eligible subjects who meet the inclusion criteria. Prior to receiving treatment with sacituzumab tirumotecan, they will be treated with trilaciclib until disease progression or intolerable toxicity occurs.\n\nRecord the dynamic changes of whole blood cell count; Hematological toxicity, including febrile neutropenia and associated infections; Transfusion of blood products and supplementation of hematopoietic raw materials. Perform tumor imaging evaluation according to RECIST 1.1. Baseline imaging examination should be conducted within 21 days prior to the first administration, and tumor imaging evaluation shall be conducted every 6 weeks (± 7 days) from the first study drug administration, or the frequency of imaging evaluation may be increased when there are clinical indications. Subjects who terminate the study drug treatment due to intolerable toxicity or other non disease progression reasons continue to receive tumor evaluation follow-up until disease progression, withdrawal from the study, or death (whichever occurs earliest).\n\nAfter the screening period and one cycle of treatment, subjects may choose to undergo whole-body PET\u002FCT imaging for exploratory analysis.",[184,185,186],"NSCLC (Advanced Non-small Cell Lung Cancer)","EGFR","Myelosuppression","2026-04-09",{"date":189,"type":40},"2026-04-14",{"date":191,"type":40},"2025-12-08",{"date":193,"type":22},"2027-12",{"name":46,"class":47},{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":146,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":204,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":214,"leadSponsor":216,"locationsCount":4},"100630347","early-phase-1-using-healthy-gut-bacteria-to-boost-immune-treatment-for-advanced-bowel-cancer-100630347","NCT07486492","Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer","An Exploratory Study of Fecal Microbiota Transplantation (FMT) Combined With Immunotherapy and Chemotherapy in Microsatellite Stable Metastatic Colorectal Cancer (MSS mCRC)","Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of MSS mCRC\n* Experienced disease progression after first-line chemotherapy and targeted therapy\n* ECOG performance status of 0-1\n\nExclusion Criteria:\n\n* History of FMT\n* Severe organ dysfunction (heart, lung, liver, kidney)\n* Other malignancies, psychiatric disorders, pregnancy or lactation\n* Unable to provide informed consent",{"count":203,"type":22},10,[102],"This research protocol outlines an exploratory study on the combination of early-life fecal microbiota transplantation (yFMT) with immunotherapy and chemotherapy in patients with microsatellite stable metastatic colorectal cancer (MSS mCRC). The single-center, single-arm study aims to assess the safety of yFMT in conjunction with immunotherapy and chemotherapy, with a secondary focus on exploring its efficacy and impact on the patients' immune microenvironment. The study will enroll 10 patients aged 18-75 who have progressed after first-line chemotherapy and targeted therapy. The intervention involves six sessions of yFMT every two weeks, alongside PD-1 inhibitor immunotherapy and FOLFIRI chemotherapy. The primary endpoints are the incidence of serious adverse events (SAEs), treatment-related adverse events (TRAEs), and intervention adjustments due to adverse events, while secondary endpoints include progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). The study is expected to last two years from initiation to data analysis completion, and it will be conducted at the Gastrointestinal Tumor Surgery Department of the First Affiliated Hospital of Xiamen University.",[207,208],"Colorectal Cancer Metastatic","Fecal Microbiota Transplantation","NOT_YET_RECRUITING","2026-03-17",{"date":212,"type":40},"2026-03-20",{"date":111,"type":22},{"date":215,"type":22},"2028-01-31",{"name":46,"class":47},{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":227,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":48},"100583341","phase-1-gb5005-cart-cell-injection-in-the-treatment-of-patients-with-cd19-positive-rr-b-nhl-100583341","NCT06875063","GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL","The Safety, Tolerability, Efficacy, and Pharmacokinetic Characteristics of GB5005 Chimeric Antigen Receptor T-cell Injection in Treating Patients With CD19-positive Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma (B-NHL).","Inclusion Criteria:\n\n1. The candidate is able to communicate effectively with researchers and sign informed consent forms in writing;\n2. Age greater than or equal to 18 years old and less than or equal to 70 years old, regardless of gender; Sign informed consent form;\n3. Non Hodgkin lymphoma confirmed by cytology and genetics;\n4. Positive expression of CD19 in tumor cells confirmed by flow cytometry or pathological histology;\n5. When screening, it meets the definition of recurrence or refractory: having received at least second-line or above systemic anti-tumor therapy (including autologous hematopoietic stem cell transplantation) containing rituximab (or other CD20 targeted drugs) and anthracycline drugs in the past, and disease progression (PD) or recurrence after the last treatment; Or recurrent patients who do not fully meet the above conditions but refuse chemotherapy and strongly demand CAR-T treatment;\n6. There is no obvious evidence of central nervous system lymphoma on brain MRI;\n7. Blood routine: Neutrophils ≥ 1.0 × 10 \\^ 9\u002FL; Hemoglobin ≥ 70 g\u002FL; Platelets ≥ 50 × 10 \\^ 9\u002FL;\n8. Coagulation function: fibrinogen ≥ 1.0 g\u002FL; Activated partial thromboplastin time (APTT) ≤ ULN+10 s, prothrombin time (PT) ≤ ULN+3 s;\n9. Liver and kidney function indicators: total bilirubin ≤ 1.5 times the upper limit of normal range (excluding Gilbert syndrome or hemolysis), ALT and AST ≤ 3.0 times the upper limit of normal range (ULN), serum creatinine ≤ 2.0 times the upper limit of normal range. If the above abnormalities are considered to be caused by tumor infiltration, they can be excluded;\n10. Assessment of left ventricular ejection fraction (LVEF) ≥ 45% using echocardiography (ECHO) or radionuclide active vascular scanning (MUGA). (After corrective treatment and meeting the criteria, it can be included in the group);\n11. Pulmonary function: Dyspnea ≤ CTCAE level 1 and SaO2 ≥ 92% in indoor air environment; 12. The physical fitness score of the Eastern Cooperative Oncology Group (ECOG) in the United States ranges from 0 to 2 points;\n12. Expected survival is greater than 6 months; 14. The subjects have sufficient levels of functional organs during screening;\n13. Female participants of childbearing age must undergo a serum pregnancy test during screening and before receiving pre-treatment chemotherapy, and the result must be negative. They are willing to use highly effective and reliable methods of contraception within one year after using the study treatment;\n14. Male participants who engage in active sexual activity with women with reproductive potential must be willing to use highly effective and reliable methods of contraception within one year after using the study treatment. Moreover, all males are strictly prohibited from donating sperm within one year after receiving research treatment infusion during the study period.\n\nExclusion Criteria:\n\n1. Patients with a history of allergies to serum albumin and DMSO in the past;\n2. Active hepatitis B virus (HBV) (HBV-DNA positive), hepatitis C virus antibody (HCV) (HCV-RNA positive), or human immunodeficiency virus (HIV) infection;\n3. Within the past 2 years, terminal organ damage caused by autoimmune diseases such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, or the need for systemic use of immunosuppressive or other systemic disease control drugs;\n4. History of unstable angina, myocardial infarction, coronary angioplasty, or significant heart disease within one year of enrollment;\n5. Primary central nervous system tumors or hematological tumors with central nervous system metastases;\n6. Uncontrolled mental illness;\n7. Merge other life-threatening severe organ failure;\n8. Participated in other clinical studies within 4 weeks;\n9. Received live vaccination within 4 weeks of enrollment;\n10. Using prohibited drugs: a. Hormones: Corticosteroids (defined as\\>20mg\u002Fday prednisone or equivalent) used at therapeutic doses within 7 days prior to leukocyte collection. But the use of physiological substitutes, local and inhaled steroids is allowed. b. Chemotherapy: rescue chemotherapy, including tyrosine kinase inhibitors (TKIs), received within 1 week before leukocyte collection. c. Donor lymphocyte infusion (DLI) received within 4 weeks before leukocyte collection. d. graft-versus-host disease (GvHD) treatment: systemic anti GVHD treatment received within 3 months before GB5005 cell infusion. e. Alenumab used within 6 months before leukocyte collection, or chlorofarabin or cladribin used within 3 months. f. Checkpoint inhibitors or stimulants used before enrollment (excluding those with more than 3 biological half lives);\n11. Patients with known history of lung injury or hemorrhagic cystitis associated with cyclophosphamide treatment;\n12. Women who are already pregnant, preparing for pregnancy during the trial period, or breastfeeding;\n\n13：As per the investigator's judgment, the subject is unlikely to complete all required visits or procedures stipulated in the protocol (including the follow-up period) or has insufficient compliance with the study.","70 Years",{"count":226,"type":22},45,[228],"PHASE1","To evaluate the safety and tolerability of GB5005 in patients with CD19-positive relapsed\u002Frefractory B-cell non-Hodgkin lymphoma (B-NHL).",[231,232,233],"Non-hodgkin Lymphoma","Refractory Lymphoma","Chimeric Antigen Receptor T-cell","2026-03-11",{"date":236,"type":40},"2026-03-13",{"date":238,"type":22},"2026-04-30",{"date":240,"type":22},"2027-05-31",{"name":46,"class":47},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":256,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":48},"100628228","dll3-targeted-petct-in-neuroendocrine-carcinoma-100628228","NCT07458906","DLL3-Targeted PET\u002FCT in Neuroendocrine Carcinoma","Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Neuroendocrine Carcinoma","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with suspected, newly diagnosed, and previously treated neuroendocrine carcinoma(supporting evidence may include imaging findings and pathology report);\n* Serum ProGRP or NSE level ≥ 3 times the upper limit of normal;\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n* Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.\n* Inability to complete PET\u002FCT imaging.",{"count":5,"type":22},[25],"The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET\u002FCT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.",[253,254,255],"DLL3-expressing Tumors","PET \u002F CT","Neuroendocrine Cancer",[257,28,255],"DLL3-expressing tumors","2026-03-04",{"date":260,"type":40},"2026-03-09",{"date":262,"type":40},"2025-12-01",{"date":264,"type":22},"2026-12-31",{"name":46,"class":47},{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":146,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":284,"locationsCount":48},"100626627","safety-tolerability-and-preliminary-efficacy-of-peginterferon--2b-in-combination-with-an-anti-pd-1-antibody-in-patients-with-advanced-or-metastatic-malignant-solid-tumors-100626627","NCT07438093","Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors","An Open-Label, Dose-Escalation Clinical Study of Peginterferon Alfa-2b in Combination With an Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Preliminary Efficacy in Patients With Advanced or Metastatic Malignant Solid Tumors","Inclusion Criteria:\n\n* 1\\. Understand and voluntarily sign the informed consent form (ICF). 2. Aged ≥18 years and ≤75 years. 3. Histologically, cytologically, or radiologically confirmed diagnosis of advanced or metastatic malignant solid tumor, with prior standard treatment failure, no standard treatment available, or intolerance to standard treatment.\n\n  4\\. At least one measurable lesion per RECIST v1.1, confirmed by computed tomography (CT) and\u002For magnetic resonance imaging (MRI).\n\n  5\\. Absolute Monocyte Count (AMC) \\\u003C0.25×10\\^9\u002FL (tested by local lab; one retest is allowed if screening AMC is between 0.25-0.35×10\\^9\u002FL).\n\n  6\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Life expectancy ≥3 months. 8. Adequate organ function within 1 week prior to first study drug administration (no transfusion or blood products, no hematopoietic growth factors for correction within 14 days prior to screening):\n* Hematology: White blood cell count ≥3.0×10\\^9\u002FL, Absolute Neutrophil Count (ANC) ≥1.5×10\\^9\u002FL, Platelet count ≥50×10\\^9\u002FL, Hemoglobin ≥90 g\u002FL.\n* Hepatic: Serum total bilirubin ≤1.5×ULN (≤3×ULN for Gilbert's syndrome); AST and ALT ≤2.5×ULN (≤5×ULN for liver metastases); Alkaline phosphatase (ALP) ≤2×ULN (≤5×ULN for bone or liver metastases).\n* Renal: Urea\u002FBUN and serum creatinine ≤1.5×ULN OR creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault formula).\n* Coagulation: International Normalized Ratio (INR) and prothrombin time (PT) ≤1.5×ULN; activated partial thromboplastin time (APTT) ≤1.5×ULN.\n\n  9\\. For women of childbearing potential: negative pregnancy test within 1 week prior to first dose. All subjects of childbearing potential and their partners must agree to use effective contraception during the study and for 6 months after the last dose.\n\n  10\\. For subjects who are HBsAg positive and\u002For HBcAb positive: HBV DNA \\\u003C2000 IU\u002FmL, must continue or initiate anti-HBV therapy (e.g., entecavir, tenofovir disoproxil fumarate). For subjects who are HCV-Ab positive: HCV RNA below the lower limit of detection.\n\nExclusion Criteria:\n\n* 1\\. History of another active malignancy within the past 5 years (except for cured malignancies like thyroid cancer, basal cell carcinoma, cervical carcinoma in situ).\n\n  2\\. Clinically significant moderate to severe ascites. 3. History of gastrointestinal hemorrhage or definitive gastrointestinal bleeding tendency within 6 months prior to study treatment.\n\n  4\\. Abdominal fistula, gastrointestinal perforation, or intraperitoneal abscess within 6 months prior to study treatment.\n\n  5\\. Known hereditary or acquired bleeding or thrombotic tendency. 6. History of thrombosis or thromboembolic events within 6 months prior to study treatment.\n\n  7\\. Poorly controlled cardiac clinical symptoms or disease. 8. Hypertension inadequately controlled by antihypertensive medication. 9. Factors affecting oral administration. 10. Prior or current central nervous system metastases. 11. HIV positive, tuberculosis positive, or co-infection with HBV and HCV. 12. Prior or planned organ or allogeneic bone marrow transplantation. 13. Interstitial lung disease that may interfere with the detection or management of suspected drug-related pulmonary toxicity.\n\n  14\\. Known or suspected active autoimmune disease. 15. Requiring systemic treatment with corticosteroids or other immunosuppressants within 14 days prior to the first study treatment.\n\n  16\\. Use of strong CYP3A4 inducers or inhibitors within 2 weeks prior to signing ICF.\n\n  17\\. Known history of severe allergy to interferon, any monoclonal antibody, or cytidine nucleoside analogue antitumor drugs.\n\n  18\\. Severe infection within 4 weeks prior to study treatment. 19. Palliative radiotherapy for non-target lesions is allowed but must be completed at least 2 weeks before study treatment.\n\n  20\\. Treatment with another investigational drug within 28 days prior to study treatment.\n\n  21\\. Major surgery or medical device treatment within 28 days prior to study treatment.\n\n  22\\. Any other condition deemed by the investigator to be inappropriate for participation in this clinical trial.",{"count":5,"type":22},[25],"This study is an open-label, dose-escalation phase I clinical trial conducted in patients with advanced or metastatic solid tumors in China.This study is an open-label, dose-escalation phase I clinical trial conducted in patients with advanced or metastatic solid tumors in China. The aim is to evaluate the safety, tolerability and preliminary efficacy of pegylated interferon alpha-2b (Peg-IFNα2b) combined with PD-1 monoclonal antibody.\n\nThe aim is to evaluate the safety, tolerability and preliminary efficacy of pegylated interferon alpha-2b (Peg-IFNα2b) combined with PD-1 monoclonal antibody.\n\nThe study adopts the classic \"3+3\" dose escalation design and plans to enroll approximately 60 patients.The study adopts the classic \"3+3\" dose escalation design and plans to enroll approximately 60 patients. The first part is the dose escalation stage, aiming to determine the maximum tolerated dose (MTD) or the recommended phase II dose (RP2D) for the combined treatment. The first part is the dose escalation stage, aiming to determine the maximum tolerated dose (MTD) or the recommended phase II dose (RP2D) for the combined treatment. The second part is the expansion stage, where the efficacy signals will be further observed at the selected dose. The second part is the expansion stage, where the efficacy signals will be further observed at the selected dose. The primary endpoints are treatment-related adverse events and dose-limiting toxicities (DLT), while the secondary endpoints include objective response rate (ORR), progression-free survival (PFS), etc. The primary endpoints are treatment-related adverse events and dose-limiting toxicities (DLT), while the secondary endpoints include objective response rate (ORR), progression-free survival (PFS), etc. The study period is planned to be 12 months. The study period is planned to be 12 months.",[277],"Advanced Solid Tumors","2026-02-26",{"date":280,"type":40},"2026-02-27",{"date":282,"type":22},"2026-04",{"date":193,"type":22},{"name":46,"class":47},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":292,"minAge":18,"maxAge":19,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":294,"briefSummary":295,"conditions":296,"keywords":299,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":48},"100611548","68ga-xacp3-petct-in-prostate-cancer-100611548","NCT07242014","68Ga-XACP3 PET\u002FCT in Prostate Cancer","PET Targeting Acid Phosphatase 3 (ACP3) in Prostate Cancer and Compared With 68Ga-PSMA","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report);\n* Patients who had scheduled both standard-of-care imaging (68Ga-PSMA PET\u002FCT) and 68Ga-XACP3 PET\u002FCT scans;\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.","MALE",{"count":5,"type":22},[25],"The objective of the study is to construct a noninvasive approach 68Ga-XACP3 PET\u002FCT to detect tumor lesions in patients with prostate cancer and to compare with 68Ga-PSMA PET\u002FCT.",[297,28,298],"Prostate Cancer","ACP3",[297,28,298],"2025-11-17",{"date":302,"type":40},"2025-11-21",{"date":304,"type":40},"2025-09-01",{"date":306,"type":22},"2027-10-01",{"name":46,"class":47},{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":315,"minAge":18,"maxAge":146,"enrollmentInfo":316,"targetDuration":4,"studyType":23,"phases":318,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":4},"100607540","phase-1-pyrotinib-maleate-tablets-in-combination-with-dalpiciclib-isethionate-tablets-and-standard-endocrine-therapy-100607540","NCT07189884","Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy","A Single-arm, Exploratory Clinical Study of Pyrotinib in Combination With Darcilib and Standard Endocrine Neoadjuvant Therapy for the Treatment of HR+HER2 Low-expression Breast Cancer","Inclusion Criteria:\n\n1. Female patients aged ≥18 years and ≤75 years old, who have just been treated for breast cancer;\n2. Pathological examination confirmed that HR was positive (ER≥10%) and HER2 was low (immunohistochemical staining ICH++ and FISH negative);\n3. Patients with invasive breast cancer confirmed by pathological examination (T≥3 or N≥1) who are eligible for neoadjuvant therapy;\n4. ECOG score 0\\~1 points;\n5. Planned to undergo definitive surgical resection of breast cancer, i.e., breast-conserving surgery or total mastectomy, sentinel lymph node (SN) biopsy, or axillary lymph node dissection (ALND);\n6. Normal function of major organs, i.e. meeting the following criteria:\n\n(1) Blood routine examination standards must meet: ANC ≥1.5×109\u002FL; PLT ≥90×109\u002FL； Hb ≥90g\u002FL； (2) Biochemical examination must meet the following criteria: TBIL ≤upper limit of normal (ULN); ALT and AST ≤ 1.5 times the upper limit of normal (ULN), alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN), BUN and Cr ≤ 1.5× ULN and creatinine clearance ≥ 50 mL\u002Fmin (CockcroftGault formula); (3) Cardiac color ultrasound and echocardiography: left ventricular ejection fraction (LVEF≥55%); (4) 18-lead ECG corrected by Fridericia's QT interval (QTcF) in women\\\u003C 470 ms; 7. For female patients who are not menopausal or surgically sterilized: agree to abstain from sexual activity or use an effective contraceptive method during the treatment period and for at least 7 months after the last dose of study treatment; 8. Volunteer to join this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Those who have a known history of allergy to the drug components of this regimen;\n2. Previous anti-tumor therapy or radiotherapy for any malignant tumor (except for cured cervical carcinoma in situ and basal cell carcinoma);\n3. Underwent major surgical procedures unrelated to breast cancer within 4 weeks, or patients have not fully recovered from such surgical procedures;\n4. Patients with stage IV (metastatic) breast cancer;\n5. Inability to swallow, intestinal obstruction, or other factors affecting drug intake and absorption;\n6. Severe heart disease or discomfort that cannot be treated;\n7. Suffering from mental illness or psychotropic substance abuse and unable to cooperate;\n8. Pregnant or lactating female patients;\n9. Patients with severe liver and kidney function diseases and hematological diseases;\n10. Those who are not suitable for enrollment in the investigator's opinion: such as a history of drug abuse, blood products, anticoagulant drugs and immunological drugs in the past year; Those with poor compliance and refusal to cooperate with treatment; Doctors with severe hypertension and diabetes are not suitable for the study.","FEMALE",{"count":317,"type":22},33,[228,150],"This study is a prospective, exploratory clinical study design, and plans to enroll 33 patients with HR+HER2 low expression breast cancer who received pyrotinib combined with darcili and standard endocrine neoadjuvant therapy to evaluate the efficacy of this regimen in HR+HER2 low expression breast cancer. Imaging evaluation was performed according to RECIST 1.1 criteria, and tumor imaging evaluation was performed by the participating center. The pathological evaluation after surgery of neoadjuvant patients was the pCR assessed by the pathologist of the participating center.",[321],"Locally Advanced Breast Cancer (LABC)","2025-09-17",{"date":324,"type":40},"2025-09-24",{"date":326,"type":22},"2025-09-23",{"date":328,"type":22},"2028-12-31",{"name":46,"class":47},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":224,"enrollmentInfo":337,"targetDuration":339,"studyType":124,"phases":4,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":4},"100603479","precise-guidance-of-adaptive-radiotherapy-for-nasopharyngeal-carcinomar-100603479","NCT07137052","Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar","A Prospective Multi-center Clinical Study on Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar by Multi-dimensional Molecular Imaging","Inclusion Criteria:\n\n1. Any sex; age 18-70 years.\n2. Histologically confirmed non-keratinizing nasopharyngeal carcinoma (World Health Organization (WHO) type II or III).\n3. Clinical stage I-IVA (American Joint Committee on Cancer (AJCC)\u002FUnion for International Cancer Control (UICC) 8th edition) with no evidence of distant metastasis.\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n5. No prior anti-tumor treatment for nasopharyngeal carcinoma, including radiotherapy, chemotherapy, immunotherapy, or biologic therapy.\n6. No contraindications to radiotherapy or chemotherapy.\n7. Adequate major organ function as defined below:\n\n   7.1 Hematology: white blood cell (WBC) ≥ 4.0 × 10\\^9\u002FL, absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL, platelet count ≥ 100 × 10\\^9\u002FL, hemoglobin ≥ 90 g\u002FL (no blood transfusion or blood products within 14 days and no use of granulocyte colony-stimulating factor (G-CSF) or other hematopoietic growth factors to correct counts);\n\n   7.2 Biochemistry: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN); blood urea nitrogen (BUN) and serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 60 mL\u002Fmin calculated by the Cockcroft-Gault formula.\n8. Participant voluntarily agrees to join the study, signs informed consent, has good compliance, and is able to attend follow-up.\n\nExclusion Criteria:\n\n1. Pathological type of keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma.\n2. History of or concurrent other active (unresolved) malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, or superficial bladder cancer.\n3. Currently participating in another clinical trial.\n4. Pregnant or breastfeeding women.\n5. Uncontrolled cardiovascular disease, including ≥ Grade II myocardial ischemia or myocardial infarction, uncontrolled cardiac arrhythmias (including corrected QT (QTc) interval ≥ 470 ms); heart failure New York Heart Association (NYHA) class III-IV, or left ventricular ejection fraction (LVEF) \\\u003C 50% on echocardiography; or myocardial infarction within the past year.\n6. Other severe comorbidities such as uncontrolled hypertension, severe cerebrovascular disease, severe renal disease, uncontrolled diabetes mellitus, or other chronic wasting diseases.\n7. History of substance or alcohol abuse, psychiatric illness, or lack of full or having limited civil capacity.\n8. In the investigator's judgment, other familial or social factors that could force premature withdrawal from the study, or other conditions likely to affect participant safety or the collection of trial data.",{"count":338,"type":22},732,"3 Years","This is an observational cohort study designed to (1) evaluate whether Gallium-68 (68Ga)-labeled fibroblast activation protein inhibitor ligand LM3 (68Ga-FAPI-LM3) positron emission tomography\u002Fcomputed tomography (PET\u002FCT) improves the accuracy of nasopharyngeal carcinoma (NPC) staging, and (2) determine whether Gallium-68-labeled programmed death-ligand 1 (68Ga-PD-L1) PET\u002FCT imaging parameters can provide early prediction of response to neoadjuvant immunotherapy. The study will assess the sensitivity and specificity of each tracer for staging and for predicting therapeutic response, analyze changes in tumor uptake parameters on 68Ga-FAPI-LM3 and 68Ga-PD-L1 PET\u002FCT before and after treatment, and compare treatment efficacy and survival outcomes between patients with different degrees of residual PET uptake and between those who did and did not receive neoadjuvant immunotherapy. The primary question it aims to answer is:\n\nDoes 68Ga-FAPI-LM3 PET\u002FCT improve the accuracy of NPC staging, and can 68Ga-PD-L1 PET\u002FCT imaging parameters provide an early prediction of response to neoadjuvant immunotherapy?\n\nParticipants will be patients with biopsy-proven nasopharyngeal carcinoma who undergo 68Ga-FAPI-LM3 and\u002For 68Ga-PD-L1 PET\u002FCT as part of clinical care or a research protocol. Tumor uptake metrics (e.g., maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic\u002Fvolumetric indices) will be measured pre- and post-treatment; diagnostic performance (sensitivity, specificity) and associations between uptake changes and clinical outcomes (response rates, progression-free and overall survival) will be calculated.",[342,254],"Nasopharyngeal Carcinoma (NPC)","2025-09-16",{"date":322,"type":40},{"date":346,"type":22},"2025-09-30",{"date":348,"type":22},"2029-01-30",{"name":46,"class":47},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":17,"minAge":357,"maxAge":146,"enrollmentInfo":358,"targetDuration":4,"studyType":23,"phases":360,"briefSummary":362,"conditions":363,"keywords":367,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":375,"locationsCount":48},"100605641","phase-4-the-effect-of-semaglutide-on-bone-health-100605641","NCT07165158","The Effect of Semaglutide on Bone Health","The Effect of Semaglutide on Osteoporotic Fractures in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n1. Type 2 diabetes (according to WHO diagnostic criteria),\n2. Age range: 50 to ≦75 years,\n3. Glycosylated hemoglobin (HbA1c): 6.5 to ≦9.0%,\n4. Bone mineral density (lumbar spine, hip, or femoral neck) T-score \\\u003C -1, or history of fragility fractures (hip, vertebral, distal forearm, or proximal humerus fractures) within three years before screening,\n5. No use of antidiabetic medications in 8 weeks prior to enrollment (excluding metformin).\n\nExclusion Criteria:\n\n1. Bone mineral density (lumbar spine, hip, or femoral neck) T-score \\\u003C -2.5,\n2. History of secondary osteoporosis,\n3. Serious liver dysfunction or chronic kidney disease (aspartate aminotransferase (AST) or alanine transaminase (ALT) \\> 2.5 times the upper limit of the normal reference, or estimated glomerular filtration rate (eGFR) \\\u003C 45 ml\u002Fmin\u002F1.73㎡),\n4. History of malignant tumors,\n5. Received strong anti-osteoporosis medications such as bisphosphonates, denosumab, or teriparatide within the past 2 years,\n6. History of pancreatitis or triglyceride levels \\>5.6 mmol\u002FL;\n7. Family history of medullary carcinoma.","50 Years",{"count":359,"type":22},150,[361],"PHASE4","Semaglutide has effects that include lowering blood sugar, reducing weight, and improving cardiovascular and renal outcomes, and it is now widely used in clinical practice. Given that weight loss is associated with bone loss, its effect on bone health has recently raised concerns. Therefore, the goal of this clinical trial is to learn the effect of semaglutide on bone mineral density and fractures in patients with type 2 diabetes.\n\nThe investigators will compare semaglutide combined with metformin to metformin alone to see if semaglutide treatment has effects on bone mineral density and bone turnover markers in patients with type 2 diabetes after 12 months.\n\nThe intervention group will receive semaglutide combined with metformin for 12 months, while the control group will receive metformin alone for the same duration. After 12 months of treatment, the investigators will compare the bone mineral density, fracture incidence, and levels of bone turnover markers between the two groups.",[364,365,366],"Osteoporosis","Osteoporosis Fracture","T2DM",[368,369,366],"antidiabetic drug","osteoporosis fracture","2025-09-11",{"date":322,"type":40},{"date":373,"type":22},"2025-09-15",{"date":264,"type":22},{"name":46,"class":47},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":385,"briefSummary":386,"conditions":387,"keywords":391,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":48},"100462759","phase-2-venetoclax-combining-chidamide-and-azacitidine-vca-in-the-treatment-of-rr-aml-100462759","NCT05305859","Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R\u002FR AML","A Multi-center, Prospective, Single-arm Study of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of Refractory\u002FRelapsed Acute Myelogenous Leukemia (R\u002FR AML)","Inclusion Criteria:\n\n* Age ≥18\n* Relapsed and refractory patients with acute myeloid leukemia via morphology and immunology\n* ECOG：0-2\n* Life expectancy ≥ 3 months\n* Adequate laboratory parameters during the screening period as evidenced by the following:\n\n  1. Creatinine clearance≥30 mL\u002Fmin and serum Creatinine ≤ 160µmol\u002FL\n  2. ALT and AST ≤ 3 × upper limit of normal (ULN)\n  3. Able to understand and sign an informed consent form (ICF).\n\nExclusion Criteria:\n\n* Diagnosis of acute promyelocytic leukemia (APL)\n* Central nervous system leukemia\n* Uncontrolled or significant cardiovascular disease, including any of the following:\n\n  1. Bradycardia of less than 50 beats per minute, unless the subject has a pacemaker; Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome);\n  2. Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg; History of clinically relevant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes);\n  3. History of second (Mobitz II) or third degree heart block (subjects with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker);\n  4. History of uncontrolled angina pectoris or myocardial infarction within 6 months prior to Screening;\n  5. History of New York Heart Association Class 3 or 4 heart failure;\n  6. Complete left bundle branch block;\n  7. Known history of left ventricular ejection fraction (LVEF) ≤45% or less than the institutional lower limit of normal;\n* Active acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy;\n* Suffered from other non-myeloid malignancies within 2 years, except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease\n* Females who are pregnant or breastfeeding;\n* Mental disorders that hinder research participation\n* Previous solid organ transplantation (SCT treatment is allowed in advance, but if the patient has GVHD or is still receiving immunosuppression\u002FGVHD treatment, it is not allowed)\n* Any other situation where the investigator believes that the patient should not participate in this trial",{"count":384,"type":22},30,[150],"The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and\u002For refractory AML",[388,389,390],"Leukemia, Myeloid, Acute","Relapsed Adult AML","Refractory Leukemia",[392],"refractory\u002Frelapsed acute myelogenous leukemia","2025-09-04",{"date":370,"type":40},{"date":396,"type":40},"2022-01-12",{"date":398,"type":22},"2027-06-30",{"name":46,"class":47},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":409,"conditions":410,"keywords":413,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":48},"100604621","petct-for-trop2-adc-response-evaluation-nsclc-100604621","NCT07151898","PET\u002FCT for Trop2 ADC Response Evaluation NSCLC","Evaluation of Treatment Response to Trop2 ADC by 68Ga-MY6349 PET\u002FCT in NSCLC","Inclusion Criteria:\n\n* adult patients (aged 18 years or order)\n* histologically or cytologically confirmed metastatic NSCLC previously treated with systemic therapy, supported by imaging (e.g. CT, MRI), tumor markers, or pathology reports\n* presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1\n* willingness to undergo serial 68Ga-MY6349 PET\u002FCT scans before and during Trop2-ADC therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee\n\nExclusion Criteria:\n\n* Evidence of significantly impaired hepatic or renal function\n* Estimated life expectancy of less than 3 months",{"count":408,"type":22},50,"To evaluate whether serial 68Ga-MY6349 PET\u002FCT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in NSCLC patients.",[411,412,28],"NSCLC","Trop2",[411,412,28,414],"Trop2-ADC","2025-08-26",{"date":417,"type":40},"2025-09-03",{"date":419,"type":40},"2025-05-01",{"date":421,"type":22},"2027-05-01",{"name":46,"class":47},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":224,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":432,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":48},"100603478","phase-2-neoadjuvant-treatment-of-locally-advanced-hypopharyngeal-cancer-with-adebrelimab-combined-with-tp-chemotherapy-regimen-100603478","NCT07137039","Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen","A Single-arm, Prospective, Single-center Clinical Study on Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen","Inclusion Criteria:\n\n* 1\\. Age: 18 to 70 years old, gender not limited;\n* 2.ECOG PS score: 0-1 point;\n* 3\\. Patients who are capable of surgical resection and willing to undergo it;\n* 4\\. Hypopharyngeal cancer diagnosed by histology\u002Fcytology and imaging, with a clinical stage of T1-2, N1-3 or T3-4, any N;\n* 5\\. At least one measurable lesion (in accordance with RECIST 1.1 standard);\n* 6\\. The expected survival period is at least 12 weeks;\n* 7\\. Other major organs (liver, kidneys, blood system, etc.) function well: Hemoglobin ≥90g\u002FL (no blood transfusion, no use of hematopoietic factors and no drug correction within 2 weeks before the first administration); Absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL; Platelet count ≥100×10\\^9\u002FL; Total bilirubin ≤1.5 times the upper limit of the normal value; Alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase ≤2.5 times the upper limit of the normal value; Serum creatinine ≤1.5 times the upper limit of the normal value, and endogenous creatinine clearance rate ≥60ml\u002Fmin; For patients who have not received anticoagulant therapy, the international normalized ratio of prothrombin time (INR) is ≤1.5, and the activated partial thromboplastin time (APTT) is ≤1.5 times the upper limit of the normal value.\n* 8\\. Female subjects with fertility must undergo a pregnancy test (serum or urine) within 72 hours before the start of the study medication, and the result must be negative. They must also be willing to use a medically approved efficient contraceptive measure (such as an intrauterine device, contraceptive pill or condom) during the study period and within 90 days after the last administration of the study drug. For male subjects whose partners are women of childbearing age, they must agree to use effective contraception or have undergone surgical sterilization during the study period and within 90 days after the last administration of the study.\n* 9\\. There is no history of allergy to related drug components.\n* 10\\. The subjects voluntarily joined this clinical study and signed the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Have received any anti-tumor treatment in the past, including radiotherapy, chemotherapy, targeted therapy, immunotherapy and traditional Chinese medicine anti-tumor treatment (except for the treatment of malignant tumors that have been completely cured in the past and have no recurrence or metastasis for ≥5 years);\n* 2\\. Have undergone surgical operations targeting the primary tumor or lymph nodes in the past;\n* 3\\. Patients who have suffered from any malignant tumors in the past five years (except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix);\n* 4\\. Patients with distant metastases;\n* 5\\. Suffering from any active autoimmune disease or a history of autoimmune diseases (such as uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after hormone replacement therapy), tuberculosis) Patients with childhood asthma that has been completely relieved and do not require any intervention or systemic treatment in adulthood (such as vitiligo, psoriasis or alopecia) can be included. However, patients who need medical intervention with bronchodilators cannot be included.\n* 6\\. Subjects who have received systemic treatment with corticosteroids (prednisone or other equivalent hormones \\>10 mg\u002F day) or other immunosuppressants within 2 weeks prior to the first administration. In the absence of active autoimmune diseases, inhalation or topical use of corticosteroids, as well as adrenal hormone replacement therapy with a dose of ≤10 mg\u002F day at the therapeutic dose of prednisone, is permitted.\n* 7\\. Those who have experienced hyperactive or venous thrombosis events within 6 months prior to enrollment, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;\n* 8\\. Within 3 months prior to enrollment, significant clinically significant bleeding symptoms or a clear bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, etc., have occurred, or are currently receiving thrombolytic or anticoagulant therapy;\n* 9\\. Those with hypertension who have not achieved good control through antihypertensive drug treatment (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg); Or grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including QTc interval ≥450ms in men and ≥470ms in women); According to the NYHA standard, patients with grade Ⅲ to Ⅳ cardiac failure, or those whose left ventricular ejection fraction (LVEF) is less than 50% as indicated by echocardiography;\n* 10\\. Urine routine test indicates urine protein ≥(++), or 24-hour urine protein content ≥1g, or severe liver and kidney dysfunction;\n* 11\\. Allergic to the test drug;\n* 12\\. Known human immunodeficiency virus (HIV) infection;\n* 13\\. Pregnant or lactating women; Subjects with fertility who are unwilling or unable to take effective contraceptive measures;\n* 14\\. Those who suffer from neurological or mental disorders and are unable to cooperate;\n* 15\\. Other circumstances that the researchers consider unsuitable for inclusion.",{"count":431,"type":22},34,[150],"To evaluate the efficacy and safety of adebrelimab combined with TP chemotherapy regimen as neoadjuvant therapy for locally advanced hypopharyngeal cancer",[435],"Locally Advanced Hypopharyngeal Cancer",[437,438,439,440],"hypopharyngeal cancer","neoadjuvant treatment","adebrelimab","chemotherapy","2025-08-15",{"date":443,"type":40},"2025-08-22",{"date":445,"type":22},"2025-08-20",{"date":447,"type":22},"2028-08-20",{"name":46,"class":47},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":121,"enrollmentInfo":456,"targetDuration":4,"studyType":23,"phases":457,"briefSummary":458,"conditions":459,"keywords":461,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":48},"100544951","phase-1-clinical-evaluation-of-177lu-ab-3prgd2-in-various-solid-tumors-with-integrin-v3-positive-expression-100544951","NCT06375564","Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression","An Open-Label, Non-Randomized, Single-Center, Investigator-Initiated Trial to Determine the Effectiveness of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression","Inclusion Criteria:\n\n1. Ability to understand and willingness to sign a written informed consent document.\n2. Age 18 and older.\n3. Confirmed unresectable or metastatic refractory cancer with measurable disease per RECIST (version 1.1) (i.e. at least 1 lesion \\> 1 cm or lymph node \\> 1.5 cm in short axis).\n4. Progressive disease after multiple-lines treatment.\n5. Eastern Cooperative Oncology Group Performance Status ≤ 3.\n6. Participant must have completed prior therapy at least 2 weeks (washout period) before 68Ga-RGD PET\u002FCT scan. Any clinically significant toxicity (with the exceptions of hair loss and sensory neuropathy) related to prior therapy resolved below Grade 2 or baseline. Completion of entry into 68Ga-RGD study and completion of the scan.\n7. Hematologic parameters are defined as Absolute neutrophil count (ANC) ≥ 1000 cells\u002Fmm3 Platelet count ≥ 50,000\u002Fmm3 Hemoglobin ≥ 8 g\u002FdL.\n8. Blood chemistry levels defined as AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN) Total bilirubin ≤ 3 times ULN Creatinine ≤ 3 times ULN Able to remain motionless for up to 30-60 minutes per scan.\n\nExclusion Criteria:\n\n1. Participant on any chemical anticoagulant including antiplatelet agents (excluding ASA).\n2. Participants with Class 3 or 4 NYHA Congestive Heart Failure.\n3. Clinically significant bleeding within two weeks before trial entry (e.g. gastrointestinal bleeding, intracranial bleeding).\n4. Pregnant or lactating women.\n5. Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e. larger than what is required for placement of a central venous access, percutaneous feeding tube, or biopsy) within 28 days before study day 1 or anticipated surgery within the subsequent 6 weeks.\n6. Has an additional active malignancy requiring therapy within the past 2 years.\n7. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.\n8. Psychiatric illness\u002Fsocial situations that would interfere with compliance with study requirements\n9. Cannot undergo PET\u002FCT scanning because of weight limits (350 lbs).\n10. INR\\>1.2; PTT\\>5 seconds above UNL.",{"count":21,"type":22},[228],"This is an open-label, non-controlled, non-randomized study to assess the therapeutic efficacy of 177Lu-AB-3PRGD2 in patients with various solid tumors who will undergo radioligand therapy using 177Lu-AB-3PRGD.",[460],"Refractory Solid Tumor",[460,462,463],"Radioligand therapy","177Lu-AB-3PRGD2","2025-08-05",{"date":466,"type":40},"2025-08-08",{"date":468,"type":40},"2024-06-12",{"date":470,"type":22},"2026-12-30",{"name":46,"class":47},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":120,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":23,"phases":479,"briefSummary":480,"conditions":481,"keywords":485,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":486,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":48},"100506391","68ga-fapi-lm3-petct-imaging-in-patients-with-fapsstr2-positive-disease-and-compared-with-18f-fdg-100506391","NCT05873777","68Ga-FAPI-LM3 PET\u002FCT Imaging in Patients With FAP\u002FSSTR2 Positive Disease and Compared With 18F-FDG","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order);\n* (ii) patients with suspected or newly diagnosed or previously malignant disease, with either FAP or SSTR2 positive expression (supporting evidence may include MRI, CT, and pathology report etc);\n* (iii) patients who had scheduled both 18F-FDG and 68Ga-FAPI-LM3 PET\u002FCT scans;\n* (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant disease;\n* (ii) patients with pregnancy;\n* (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":384,"type":22},[25],"As a new dual receptor (SSTR2 and FAP) targeting PET radiotracer, 68Ga-FAPI-LM3 is promising as an excellent imaging agent applicable to SSTR2 positive diseases. In this research, we investigate the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-LM3 in healthy volunteers. Moreover, we evaluate the potential usefulness of 68Ga-FAPI-LM3 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of lesions in SSTR2 positive diseases, and compared with 18F-FDG PET\u002FCT.",[482,483,484],"SSTR2","FAP","Positron-Emission Tomography",[482,483,484],{"date":466,"type":40},{"date":488,"type":40},"2023-04-09",{"date":490,"type":22},"2025-12-31",{"name":46,"class":47},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":501,"conditions":502,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":48},"100595706","t-cell-developmental-status-in-patients-with-malignant-hematological-tumors-100595706","NCT07035938","T-cell Developmental Status in Patients With Malignant Hematological Tumors","An Observational, Bidirectional Cohort Study to Evaluate T-cell Developmental Status in Patients With Malignant Hematological Tumors","Inclusion Criteria:\n\n1. Age ≥ 18 years; both genders included; expected survival \\> 3 months;\n2. Cohort 1: Patients with newly diagnosed or relapsed B-cell lymphoma confirmed by histopathology, bone marrow pathology, flow cytometry, morphology, and genetic testing; Cohort 2: Patients with newly diagnosed or relapsed multiple myeloma confirmed by the same methods; Cohort 3: Healthy volunteers;\n3. Able to understand and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Significant pulmonary disease:\n\n   Chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) \\\u003C50% of predicted normal value. Note: Suspected COPD cases require FEV1 testing; subjects with FEV1 \\\u003C50% of predicted must be excluded.\n\n   Moderate\u002Fsevere persistent asthma within the past 2 years, or currently uncontrolled asthma of any severity. (Note: Controlled intermittent or mild persistent asthma is permitted.)\n2. Symptomatic congestive heart failure (NYHA Class II-IV), symptomatic\u002Funcontrolled arrhythmias, congenital long QT syndrome, or corrected QT interval (QTc) \\>500 ms (Fridericia formula) at screening.\n3. History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pneumonitis, or severely impaired lung function.\n4. HIV infection (positive HIV-1\u002F2 antibodies) or known syphilis infection.\n5. Unhealed wounds, fractures, gastroduodenal ulcers, persistent fecal occult blood positivity, ulcerative colitis, or other conditions at risk of gastrointestinal bleeding\u002Fperforation (as determined by the investigator).\n6. Severe neurological\u002Fpsychiatric disorders, immunodeficiency, hepatitis\u002Fcirrhosis, or other conditions deemed unsuitable for study participation by the investigator.",{"count":500,"type":22},75,"To evaluate the immune status and prognosis of patients with malignant hematological tumors, thereby guiding clinical therapeutic strategies.",[503],"Hematologic Malignancy","2025-07-19",{"date":506,"type":40},"2025-07-23",{"date":508,"type":40},"2025-06-22",{"date":510,"type":22},"2028-06-30",{"name":46,"class":47},{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":23,"phases":521,"briefSummary":522,"conditions":523,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":526,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":48},"100566182","phase-2-large-fraction-radiation-therapy-combined-with-lenalidomide-and-glofitamab-in-refractory-relapsed-dlbcl-100566182","NCT06651853","Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL","The Efficacy and Safety of Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab Monoclonal Antibody in the Treatment of Refractory Relapsed Diffuse Large B-cell Lymphoma Patients","Inclusion Criteria:\n\n1. Written informed consent must be obtained before any trial-related procedures are implemented.\n2. Participants must be aged 18 or older, of any gender, with an expected survival period of more than 3 months.\n3. ECOG PS score must be between 0-3.\n4. Participants must have histopathologically confirmed diffuse large B-cell lymphoma.\n5. Patients who have failed first-line standard treatment (patients with relapsed disease \\\u003C 12 months or primary refractory disease, or relapsed disease \\> 12 months but are transplant-ineligible after 1 line of systemic therapy, or relapsed disease after 2+ lines of therapy). Participants with central nervous system metastasis can be included.\n6. Participants must not have received bispecific antibody therapy in the past.\n7. B-cell non-Hodgkin's lymphoma must have at least one measurable lesion according to RECIST1.1 criteria.\n8. Participants must have sufficient organ function, meeting the following:\n\n   laboratory criteria: (1) Total bilirubin ≤1.5× upper limit of normal (ULN); (2) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5× ULN; (3) Blood creatinine ≤1.5× ULN and creatinine clearance rate (calculated using the Cockcroft-Gault formula) ≥60 ml\u002Fmin; (4) Good coagulation function, defined as an international normalized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN.\n9. For women of childbearing potential, a urine or serum pregnancy test must be conducted within 3 days before the first administration of the study drug (Day 1 of Cycle 1) and the results must be negative. If the results of the urine pregnancy test cannot be confirmed as negative, a blood pregnancy test is required. Non-childbearing women are defined as those who have been menopausal for at least 1 year, or who have undergone surgical sterilization or hysterectomy.\n10. If there is a risk of pregnancy, all participants (both male and female) must use contraception with an annual failure rate of less than 1% throughout the treatment period and for 120 days after the last administration of the study drug (or 180 days after the last chemotherapy administration).\n\nExclusion Criteria:\n\n1. B-cell non-Hodgkin's lymphoma with loss of CD20 expression.\n2. Acute or chronic active Hepatitis B or C infection, Hepatitis B virus (HBV) DNA\\>2000IU\u002Fml or 104 copies\u002Fml; Hepatitis C virus (HCV) RNA\\>103 copies\u002Fml; simultaneous positivity for Hepatitis B surface antigen (HbsAg) and anti-HCV antibody.\n3. Participants have received anti-hematologic malignancy treatment within 2 weeks before the start of treatment or within 5 half-lives of the drug, whichever is longer.\n4. Bone marrow insufficiency defined by platelet count \\\u003C30 x 109\u002FL or absolute neutrophil count \\\u003C1.0 x 109\u002FL.\n5. Participants with clinically significant pulmonary disease, including (1) participants with chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) \\\u003C50% of the predicted normal value. Note that participants suspected of having COPD need to undergo an FEV1 test, and if FEV1\\\u003C50% of the predicted normal value, the participant must be excluded. (2) Participants with moderate or severe persistent asthma in the past 2 years, or currently have any category of uncontrolled asthma. (Note that participants currently with controlled intermittent asthma or controlled mild persistent asthma can participate in this study).\n6. Uncontrolled hypertension, with systolic blood pressure \\>150mmHg or diastolic blood pressure \\>90mmHg after optimal medical treatment, history of hypertensive crisis or hypertensive encephalopathy.\n7. Symptomatic congestive heart failure (New York Heart Association class II-IV). Symptomatic or poorly controlled arrhythmias. History of congenital long QT syndrome or a corrected QTc \\>500ms (calculated using the Fridericia method) at screening.\n8. Large fraction radiation therapy received within 4 weeks prior to the first treatment. For patients who received radiation therapy more than 4 weeks before the first treatment, all the following conditions must be met to be included: there are currently no radiation-related toxic reactions, no need to take glucocorticoids, excluding radiation pneumonia, radiation hepatitis, radiation enteritis, etc.\n9. Patients who have difficulty swallowing oral medications.\n10. Past and current history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, severe impairment of lung function, and other lung diseases.\n11. Human immunodeficiency virus (HIV) infection (HIV 1\u002F2 antibody positive), known syphilis infection.\n12. Presence of unhealed wounds, fractures, gastric and duodenal ulcers, persistent fecal occult blood positivity, ulcerative colitis, etc., or other conditions that the investigator determines may cause gastrointestinal bleeding or perforation.\n13. Active or poorly controlled severe infection. Severe infection within 4 weeks before the first administration, including but not limited to hospitalization for complications of infection, sepsis, or severe pneumonia.\n14. Major surgical treatment or significant traumatic injury received within 4 weeks before the first administration.\n15. Traditional Chinese medicine with anti-tumor indications received within 2 weeks before the first administration.\n16. Known allergy to any component of bispecific antibodies or GM-CSF formulations.\n17. Treatment in another clinical trial within 4 weeks before the first administration.\n18. Pregnant or breastfeeding female patients.\n19. Presence of any active autoimmune disease or history of autoimmune disease (such as but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis; participants who need bronchodilators for medical intervention for asthma cannot be included); but the following patients are allowed to participate: vitiligo, psoriasis, alopecia, well-controlled type I diabetes that does not require systemic treatment, and hypothyroidism with normal thyroid function through replacement therapy.\n20. Other acute or chronic diseases, mental illnesses, or abnormal laboratory test values that may lead to the following results: increase the risk associated with study participation or administration of the study drug, or interfere with the interpretation of study results, and according to the investigator's judgment, the patient is deemed ineligible to participate in this study.",{"count":520,"type":22},22,[150],"To prospectively evaluate the efficacy and safety of large fraction radiation therapy combined with granulocyte-macrophage colony-stimulating factor, lenalidomide, and glofitamab monoclonal antibody in the treatment of refractory relapsed diffuse large B-cell lymphoma patients",[524,525],"Diffuse Large B-cell Lymphoma","Relapsed and Refractory",{"date":506,"type":40},{"date":528,"type":40},"2024-10-21",{"date":530,"type":22},"2028-07-30",{"name":46,"class":47},{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":539,"enrollmentInfo":540,"targetDuration":4,"studyType":23,"phases":541,"briefSummary":542,"conditions":543,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":48},"100599495","phase-2-iparomlimabtuvorlimab-ql1706-and-modified-tpf-regimen-for-induction-therapy-in-lanpc-100599495","NCT07085234","Iparomlimab\u002FTuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC","The Efficacy and Safety of Iparomlimab\u002FTuvorlimab (QL1706) Combined With Modified TPF Regimen for Induction Therapy in Locally Advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Age: ≥ 18 years old;\n* Patients with nasopharyngeal carcinoma diagnosed by pathology (including histology or cytology), with a clinical stage of III - IV (excluding T3N0 - 1) (according to the UICC\u002FAJCC TNM staging system (8th edition));\n* No prior systematic treatment (surgery, radiotherapy, chemotherapy, etc.); At least one measurable lesion on imaging examination (according to RECIST criteria version 1.1);\n* ECOG PS: 0 - 1 points;\n* Expected survival time ≥ 3 months;\n* Normal function of major organs, meeting the following criteria:\n\n  1. Blood routine tests should meet the following (without blood transfusion within 14 days):\n\n     1. HB ≥ 100 g\u002FL,\n     2. WBC ≥ 3 × 10⁹\u002FL,\n     3. ANC ≥ 1.5 × 10⁹\u002FL,\n     4. PLT ≥ 100 × 10⁹\u002FL;\n  2. Biochemical tests should meet the following criteria:\n\n     1. BIL \\\u003C 1.5 times the upper limit of normal (ULN),\n     2. ALT and AST \\\u003C 2.5 ULN, GPT ≤ 1.5 × ULN;\n     3. Serum Cr ≤ 1 ULN, endogenous creatinine clearance rate \\> 60 ml\u002Fmin (Cockcroft - Gault formula);\n* Male subjects and women of childbearing potential must use contraception from the start of the first dose of the study drug until 24 weeks after the last dose of the study drug;\n* Normal function of major organs, with basically normal blood routine, blood biochemistry and coagulation function tests;\n* The investigator believes that the patient will benefit from the treatment in terms of survival;\n* The patient voluntarily participates in this study and provides a written informed consent form.\n\nExclusion Criteria:\n\n* Active, known, or suspected autoimmune diseases;\n* Patients with hypertension whose blood pressure cannot be controlled within the normal range with antihypertensive medications (systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 90 mmHg);\n* Inherited bleeding tendency or coagulation disorders. Clinically significant bleeding symptoms occurred within 12 weeks before screening or there is a definite bleeding tendency (cumulative blood loss exceeding 50 ml within 24 hours);\n* Uncontrolled cardiac clinical symptoms or diseases, such as: (1) Heart failure of NYHA class II or above; (2) Unstable angina; (3) Myocardial infarction within 24 weeks; (4) Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n* Interstitial lung disease, drug-induced pneumonia, radiation pneumonia requiring steroid treatment, active pneumonia with clinical symptoms, or severe pulmonary function impairment;\n* Subjects with active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 10⁴ copies\u002FmL) or hepatitis C (positive for hepatitis C antibody and HCV-RNA above the lower limit of detection of the analytical method);\n* Subjects with allergic reactions to the drugs used in this study;\n* Pregnant or lactating women;\n* Other conditions considered by the investigator as unsuitable for participation in this study.","65 Years",{"count":384,"type":22},[150],"This is a prospective, open-label, multicenter, single-arm clinical study. A total of 30 patients with locally advanced nasopharyngeal carcinoma who have not received prior systemic treatment are planned to be enrolled at three centers. After enrollment, the patients will receive induction therapy with Iparomlimab\u002FTuvorlimab(QL-1706) in combination with a modified TPF regimen, followed by concurrent chemoradiotherapy with cisplatin according to the standards of clinical practice.",[544,545,546],"Locally Advanced Nasopharyngeal Carcinoma","Immunotherapy","Induction Therapy","2025-07-17",{"date":549,"type":40},"2025-07-25",{"date":551,"type":22},"2025-07-30",{"date":553,"type":22},"2029-12-31",{"name":46,"class":47},{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":315,"minAge":18,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":563,"conditions":564,"keywords":566,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":574,"locationsCount":48},"100596532","petct-for-trop2-adc-response-evaluation-cancers-100596532","NCT07046689","PET\u002FCT for Trop2 ADC Response Evaluation Cancers","Evaluation of Treatment Response to Trop2 ADC by 68Ga-MY6349 PET\u002FCT in Advanced Breast Cancer","Inclusion Criteria:\n\n* adult patients (aged 18 years or order)\n* histologically or cytologically confirmed metastatic breast cancer previously treated with systemic therapy, supported by imaging (e.g., MRI, CT), tumor markers, or pathology reports\n* presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1\n* willingness to undergo serial 68Ga-MY6349 PET\u002FCT scans before and during Trop2-ADC therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee\n\nExclusion Criteria:\n\n* Evidence of significantly impaired hepatic or renal function\n* Estimated life expectancy of less than 3 months",{"count":408,"type":22},"To evaluate whether serial 68Ga-MY6349 PET\u002FCT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in breast cancer patients.",[565,412,28],"Breast Cancer",[567,412,28,414],"Breast cancer","2025-07-14",{"date":570,"type":40},"2025-07-15",{"date":572,"type":40},"2024-11-01",{"date":264,"type":22},{"name":46,"class":47},{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":584,"conditions":585,"keywords":587,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":593,"locationsCount":48},"100596533","68ga-my6349-petct-in-solid-tumors-100596533","NCT07046702","68Ga-MY6349 PET\u002FCT in Solid Tumors","68Ga-MY6349 PET\u002FCT in Solid Tumors and Compared With 18F-FDG PET\u002FCT","Inclusion Criteria:\n\n* adult patients (aged 18 years or older)\n* patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report)\n* patients who had scheduled both standard-of-care imaging and 68Ga-MY6349 PET\u002FCT scans\n* patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee\n\nExclusion Criteria:\n\n* patients with pregnancy\n* the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent",{"count":583,"type":22},300,"The objective of the study is to construct a noninvasive approach 68Ga-MY6349 PET\u002FCT to detect the Trop-2 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from Trop-2 PET\u002FCT.",[586,412,28],"Solid Tumor",[588,412,28],"Solid tumor",{"date":570,"type":40},{"date":591,"type":40},"2024-12-10",{"date":264,"type":22},{"name":46,"class":47},""]